Business Context and Reporting Period
This Form 8-K filing by Zafgen, Inc. (not Larimar Therapeutics, Inc.) reports on the Annual Meeting of Stockholders held on June 25, 2015. The record date for the meeting was April 27, 2015, with 26,894,157 outstanding shares of common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders voted on three proposals, all of which were approved:
- Proposal 1 (Director Election): Bruce Booth, Ph.D., and Avi Goldberg were elected as Class I directors for a three-year term.
- Proposal 2 (Auditor Ratification): PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2015.
- Proposal 3 (Compensation Plan): The 2014 Stock Option and Incentive Plan was ratified.
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Proposal 1 (Bruce Booth) | 20,071,167 | 1,974,229 | 116,377 | 1,388,714 |
| Proposal 1 (Avi Goldberg) | 20,338,906 | 1,706,460 | 116,407 | 1,388,714 |
| Proposal 2 (Auditor) | 23,546,327 | 3,314 | 846 | N/A |
| Proposal 3 (Stock Plan) | 16,702,326 | 5,071,986 | 387,461 | 1,388,714 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the company name discrepancy: The input metadata lists "Larimar Therapeutics, Inc.," but the filing is for "Zafgen, Inc."
- Confirm the election of Bruce Booth and Avi Goldberg to the Board of Directors.
- Note the significant number of "Against" votes (approx. 5 million) on Proposal 3 regarding the Stock Option and Incentive Plan.
- Review the Definitive Proxy Statement filed on April 30, 2015, for detailed descriptions of the proposals.